The FDA granted an emergency use authorization to Qiagen (NYSE:QGEN) for a diagnostic test that the company said can differentiate among COVID-19 and 20 other respiratory diseases that cause similar symptoms, the company said today. The SARS-CoV-2 Panel test works in about an hour, according to Netherlands-based Qiagen. It is a multiplexed nucleic acid test […]
Thermo Fisher Scientific (NYSE:TMO) confirmed in a prospectus supplement that it is in part financing its $11.5 billion purchase of Qiagen (NYSE:QGEN) with an offering worth $2.2 billion. The offering includes $1.1 billion in 4.133% senior notes due in 2025 and another $1.1 billion in 4.497% senior notes due in 2030. Thermo Fisher said in its prospectus […]
Thermo Fisher Scientific (NYSE:TMO) and Qiagen (NYSE:QGEN) announced today that their boards have unanimously approved Thermo Fisher’s proposal to acquire Qiagen for approximately $11.5 billion. The proposal is that Thermo Fisher will acquire Qiagen for €39 per share in cash, or $43.53. That price represents a premium of approximately 23% of the closing price of Qiagen’s common […]
Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top devices for fast and early detection of diseases, according to the complaint, filed in U.S. District […]
Qiagen (NYSE:QGEN) today touted the FDA’s approval of its PartoSure diagnostic test, designed to assess the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The non-invasive strip test detects placental alpha microglobulin-1 and can provide results in less than five minutes, according to Germany-based Qiagen. Get the full story at our sister […]
Qiagen (NYSE:QGEN) today launched two liquid biopsy panels designed to evaluate circulating tumor cells isolated from a patient’s blood samples. The company’s lung and prostate cancer diagnostic tests will be introduced at the annual meeting of the American Association for Cancer Research in Chicago, according to Qiagen. Get the full story at our sister site, Drug […]
Here’s a roundup of companies announcing new distribution deals.
Qiagen N.V. (NSDQ:QGEN) and Abbott (NYSE:ABT) entered an agreement that boosts each company’s automated in vitro diagnostic product offerings in the U.S. and Canada.
The supply deal involves the exchange of components for the respective companies’ diagnostic products, designed to make their respective automation platforms and infectious disease testing products more competitive.
Qiagen N.V. (NSDQ:QGEN) posted fourth-quarter sales of $289.1 million for the three months ended Dec. 31, 2009, up 22 percent compared with $237.2 million during the same period in 2008. Net income rose 32 percent to $57.6 million, compared with $43.7 million during Q4 2008:
QIAGEN Reports Strong Fourth Quarter and Fiscal 2009 Results
Fiscal 2009 Net Sales Exceed $1 Billion